首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing
【24h】

Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing

机译:TP53肿瘤抑制基因突变的阵列引物延伸重测序:与变性HPLC和直接测序的比较

获取原文
           

摘要

Mutations of TP53 (17p13.1; OMIM 191170; PubMed accession number X54156) are common in cancers and are typically missense within exons 4–9, impairing the capacity of p53 to transactivate genes involved in cell cycle arrest, apoptosis, and DNA repair (1). Functionally, mutations may differ according to their nature and position, as well as to the presence of a common polymorphism at codon 72 (arginine or a proline) in the mutant allele (2). Knowing TP53 mutation status has potential applications for cancer prognosis (3)(4) and early diagnosis (5), identification of mutagen “fingerprints” (1)(6), and prediction of therapeutic outcomes (7)(8). To achieve this purpose, sensitive, fast, and cost-effective methods are needed to assess the whole coding sequence plus exon/intron boundaries. Current approaches are based on mutation prescreening with single strand conformational polymorphism analysis, temporal temperature gradient electrophoresis, or denaturing HPLC (DHPLC) combined with direct sequencing of relevant PCR fragments [reviewed in Ref. (9)]. These methods are labor-intensive, difficult to standardize, and in some cases, of limited sensitivity. In recent years, 2 microarray methods for resequencing TP53 have been described: the Affymetrix p53 GeneChip array, described elsewhere (10)(11), and the Arrayed Primer Extension (APEX), based on incorporation of 4 dye terminators into oligonucleotide primers that each identify a base in the target sequence (12). In 2002, we described an APEX array for resequencing TP53 exons 2–9, which contain 95% of known mutations in TP53 (13). Here we compare the sensitivity and detection limits of APEX with a standard method, DHPLC/direct sequencing, and discuss the potential of APEX for application to cancer diagnostic or prognostic purposes.Specimens in the comparison set included 6 cell lines with mutations in different TP53 exons (see Table 1 of the Data Supplement that accompanies the online version of this Technical …
机译:TP53突变(17p13.1; OMIM 191170; PubMed登录号X54156)在癌症中很常见,并且通常在第4-9外显子中是错义的,从而削弱了p53激活涉及细胞周期阻滞,凋亡和DNA修复的基因的能力( 1)。从功能上讲,突变可能会因其性质和位置以及突变等位基因中第72个密码子(精氨酸或脯氨酸)的共同多态性而异(2)。知道TP53突变状态在癌症预后(3)(4)和早期诊断(5),诱变“指纹”的识别(1)(6)以及治疗结果的预测(7)(8)中具有潜在的应用。为了实现此目的,需要灵敏,快速且经济高效的方法来评估整个编码序列以及外显子/内含子边界。目前的方法是基于单链构象多态性分析,时间温度梯度电泳或变性HPLC(DHPLC)的突变预筛选,并结合相关PCR片段的直接测序。 (9)]。这些方法劳动强度大,难以标准化,并且在某些情况下灵敏度有限。近年来,已经描述了两种用于重新测序TP53的微阵列方法:Affymetrix p53 GeneChip阵列(在别处描述了(10)(11))和基于4种染料终止子掺入寡核苷酸引物中的阵列引物扩展(APEX)。识别靶序列中的碱基(12)。在2002年,我们描述了一个APEX阵列,用于对TP53外显子2–9进行重测序,其中包含95%的TP53已知突变(13)。在这里,我们将APEX的灵敏度和检测限与标准方法DHPLC /直接测序进行了比较,并讨论了APEX在癌症诊断或预后方面的潜力。比较集中的标本包括6个在不同TP53外显子中具有突变的细胞系(请参阅本技术资料在线版本随附的数据补充表1)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号